Search Within

Alexander Meyer Lesokhin

Formats
  1. Meeting Abstract (252)
  2. Journal Article (103)
  3. Research Letter (11)
  4. Review (7)
  5. Correspondence (4)
  6. Book Section (2)
  7. Editorial (2)
Groups
  1. Center for Hematologic Malignancies (381)
  2. Department of Medicine (381)
  3. Hematologic Malignancies Research (381)
  4. Hematologic Malignancies, Division of (381)
  5. Myeloma (381)
  6. Survivorship Research (225)

More Groups

People
  1. Hani Hassoun (202)
  2. Heather Landau (187)
  3. Sergio Giralt (185)
  4. David Chung (175)
  5. Neha Korde (174)
  6. Sham Mailankody (170)

More People

Years
  1. 2025 (12)
  2. 2024 (52)
  3. 2023 (77)
  4. 2022 (51)
  5. 2021 (31)
  6. 2020 (18)

More Years

Publications
  1. Blood (140)
  2. Clinical Lymphoma, Myeloma and Leukemia (57)
  3. Journal of Clinical Oncology (41)
  4. Biology of Blood and Marrow Transplantation (13)
  5. Leukemia and Lymphoma (13)
  6. Blood Advances (12)

More Publications

Publishers
  1. American Society of Hematology (152)
  2. Elsevier Inc. (79)
  3. American Society of Clinical Oncology (41)
  4. Nature Publishing Group (26)
  5. American Association for Cancer Research (14)
  6. Taylor & Francis Group (13)

More Publishers

Results (381)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies
    Journal Article

    Armand, P.; Lesokhin, A.; Borrello, I.; Timmerman, J.; Gutierrez, M.; Zhu, L.; McKiver, M. P.; Ansell, S. M.
    Leukemia (2021)

    Fulltext@MSK | Save
  • Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: A multicenter observational study
    Journal Article

    Khan, N.; Lindner, S.; Gomes, A. L. C.; Devlin, S. M.; Shah, G. L.; Sung, A. D.; Sauter, C. S.; Landau, H. J.; Dahi, P. B.; Perales, M. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy
    Journal Article

    Eveillard, M.; Korde, N.; Ciardiello, A.; Diamond, B.; Lesokhin, A.; Mailankody, S.; Smith, E.; Hassoun, H.; Hultcrantz, M.; Shah, U.; more...
    Clinica Chimica Acta (2021)

    Fulltext@MSK | Save
  • COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: A cohort study from five academic centers
    Journal Article

    Hultcrantz, M.; Richter, J.; Rosenbaum, C. A.; Patel, D.; Smith, E. L.; Korde, N.; Lu, S. X.; Mailankody, S.; Shah, U. A.; Lesokhin, A. M.; more...
    Blood Cancer Discovery (2020)

    Fulltext@MSK | Save
  • VRd versus KRd safety profiles in newly diagnosed multiple myeloma patients using real-world evidence data from a single institution: VRd has high rates of chronic neuropathy, and KRd has low rates of cardiopulmonary or renal toxicities when using optimized IV fluid management coupled with baseline cardiac workup
    Meeting Abstract

    Tan, C.; Diamond, B.; Hultcrantz, M.; Korde, N.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Lu, S. X.; Patel, D.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders: A population based study including 94,579 cases and 368,348 matched controls
    Meeting Abstract

    Shah, U. A.; Rögnvaldsson, S.; Derkach, A.; Björkholm, M.; Turesson, I.; David, Y.; Hultcrantz, M.; Tan, C.; Hassoun, H.; Korde, N.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A pilot study evaluating lenalidomide and CC-486 in combination with radiotherapy for patients with plasmacytoma (LENAZART study)
    Meeting Abstract

    Shah, U. A.; Werner, K.; Tavitian, E.; Devlin, S.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Tan, C.; Lu, S. X.; Smith, E. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Investigational CD47-blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: Update from the ongoing first-in-human dose escalation study
    Meeting Abstract

    Patel, K.; Ramchandren, R.; Maris, M.; Lesokhin, A. M.; von Keudell, G. R.; Cheson, B. D.; Zonder, J.; Seymour, E. K.; Catalano, T.; Lin, G. H. Y.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • CARTITUDE-1: Phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed/refractory multiple myeloma
    Meeting Abstract

    Madduri, D.; Berdeja, J. G.; Usmani, S. Z.; Jakubowiak, A.; Agha, M.; Cohen, A. D.; Stewart, A. K.; Hari, P.; Htut, M.; O'Donnell, E.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Preliminary safety, efficacy, pharmacokinetics, and pharmacodynamics of subcutaneously (SC) administered PF-06863135, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Lesokhin, A. M.; Levy, M. Y.; Dalovisio, A. P.; Bahlis, N. J.; Solh, M.; Sebag, M.; Jakubowiak, A.; Jethava, Y. S.; Costello, C. L.; Chu, M. P.; more...
    Blood (2020)

    Fulltext@MSK | Save